Joint recommendations for retinal screening in long‐term users of hydroxychloroquine and chloroquine in the United Kingdom, 2018
Hydroxychloroquine has become established in the management of various forms of cutaneous lupus, photosensitive dermatoses, porphyria cutanea tarda, cutaneous sarcoid, lichen planus and other inflammatory dermatological diseases.1 Dermatologists who prescribe hydroxychloroquine should be aware of ne...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Published: |
Wiley
2018
|
| Summary: | Hydroxychloroquine has become established in the management of various forms of cutaneous lupus, photosensitive dermatoses, porphyria cutanea tarda, cutaneous sarcoid, lichen planus and other inflammatory dermatological diseases.1 Dermatologists who prescribe hydroxychloroquine should be aware of new recommendations for retinal screening in all patients on long‐term hydroxychloroquine and chloroquine in the United Kingdom.2 The recommendations have been published by the Royal College of Ophthalmologists following a systematic review of the current evidence with input from representatives from the British Society for Rheumatology (BSR)3 and the British Association of Dermatologists (BAD) (Dr. M Ardern‐Jones). The recommendations do not apply to mepacrine or quinacrine. |
|---|